Lenz Therapeutics has raised $83.5 million in an oversubscribed Series B financing, according to a press release.
“With our recent $83.5 million Series B financing, Lenz is well capitalized to complete our ongoing phase 3 studies for presbyopia as well as potential approval and commercial launch of our aceclidine-based presbyopia eye drop,” Eef Schimmelpennink, president and CEO of Lenz, told Healio/OSN.
The financing was led by new investor Sectoral Asset Management, with other new investors including Alpha Wave Ventures and Point 72. Existing investors included RA Capital